drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (allogeneic CAR-NK cell therapy)
drug_description
Allogeneic cord blood–derived NK cells engineered to express a CD5-directed chimeric antigen receptor and constitutive IL-15 with an inducible caspase 9 (iC9) safety switch; redirects NK cytotoxicity to CD5+ malignant lymphocytes and supports NK survival and persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic cord blood–derived NK cells engineered with a CD5-specific chimeric antigen receptor to redirect NK cytotoxicity against CD5+ malignant lymphocytes. A constitutive IL-15 transgene enhances NK survival, proliferation, and persistence, while an inducible caspase-9 (iC9) safety switch enables rapid elimination of the cells if severe toxicity occurs.
drug_name
iC9/CD5CAR/IL-15 cord blood–derived NK cells (CAR-NK)
nct_id_drug_ref
NCT05110742